Cardiovascular
St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013
May 9, 2013 1:55 pm | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has conducted a further independent analysis of data received from...
New Four-Year Data From Boston Scientific Demonstrated WATCHMAN Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial
May 9, 2013 12:02 pm | by The Associated Press | News | CommentsBoston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN@ Left Atrial Appendage (LAA) Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic...
First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ™ Pulmonary Vein Isolation System™ in the Treatment of Paroxysmal Atrial Fibrillation
May 9, 2013 9:49 am | by The Associated Press | News | CommentsDIAMOND BAR, Calif.--(BUSINESS WIRE)--May 9, 2013--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, today announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of...
Thoracic Endografts Used Successfully to Remove Tumors Invading the Aorta
May 8, 2013 10:43 am | by American Association for Thoracic Surgery | News | CommentsSome chest tumors may invade one of the great vessels of the body, the aorta. Surgical removal of these tumors is very challenging and necessitates the support of a heart-lung machine. Therefore, there is an increased risk of complication and death. In a small series of patients, placing a stent within the aorta facilitated the subsequent removal of tumor and eliminated the need for heart-lung bypass.
Heart Rhythm 2013 - ScottCare Launches Innovations in Universal Management of Cardiac Implantable Electronic Device (CIED) Data
May 8, 2013 9:00 am | by The Associated Press | News | CommentsCLEVELAND--(BUSINESS WIRE)--May 8, 2013--As a technology leader in devices and software for cardiology diagnosis, therapy and rehabilitation, ScottCare will unveil new advances in importing, monitoring and reviewing CIED data at this year’s Heart Rhythm Society’s Scientific Session, Heart Rhythm...
St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices
May 8, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy...
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States
May 8, 2013 7:00 am | by The Associated Press | News | CommentsSUNNYVALE, Calif--(BUSINESS WIRE)--May 8, 2013--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration (FDA) to initiate patient enrollment...
Demand for Hybrid Solutions to Spur European Interventional Radiology and Cardiology Markets, finds Frost & Sullivan
May 8, 2013 4:00 am | by PR Newswire | News | CommentsLONDON, May 8, 2013 /PRNewswire/ -- The European market for interventional radiology and cardiology is heading towards maturity, especially in Western Europe. Although the economic slowdown and fewer orders had a negative impact on revenues in 2012, it is expected that expanding...
A Living Patch for Damaged Hearts
May 7, 2013 10:10 am | by Duke University | News | CommentsDuke University biomedical engineers have grown three-dimensional human heart muscle that acts just like natural tissue. This advancement could be important in treating heart attack patients or in serving as a platform for testing new heart disease medicines.
FDA Approves BIOTRONIK’s Ilesto 7 ICD/CRT-D Series
May 7, 2013 10:02 am | by The Associated Press | News | CommentsLAKE OSWEGO, Ore.--(BUSINESS WIRE)--May 7, 2013--BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced that the Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator...
Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups For On-X® Prosthetic Heart Valve Anticoagulation Clinical Study
May 7, 2013 9:00 am | by The Associated Press | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--May 7, 2013--On-X ® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated with US FDA...
The Future of Energy-Based Surgical Systems
May 6, 2013 2:43 pm | by Steven Walsh, Ph.D., VP of R&D, and Nikolay Suslov, Ph.D., EVP and CTO, Plasma Surgical | Blogs | CommentsUnique energy-based surgical devices afford broad clinical use in the cutting, coagulation, and ablation of tissues using a high velocity jet of thermal plasma, and the PlasmaJet surgical system is one example of this medical device evolution. Plasma is formed when sufficient energy is added to remove outer electrons from a gas to form ions.
Medtronic Announces FDA Approval of New Portfolio Of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-Defibrillators
May 6, 2013 10:18 am | by Medtronic | News | CommentsMedtronic, Inc. has announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva® portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibrillators (ICD).
AATS Report: Prospective Randomized On-X Heart Valve Clinical Trial (PROACT) Provides Evidence of Reduced Complications
May 6, 2013 9:00 am | by The Associated Press | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--May 6, 2013--On-X ® Life Technologies, Inc. (On-X LTI) announced today that interim results for the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT) are being presented at the American Association for Thoracic Surgery Annual (AATS) meeting by John...
AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
May 6, 2013 9:00 am | by PR Newswire | News | CommentsBOSTON, May 6, 2013 /PRNewswire/ -- AG Mednet today announced a new core lab partnership with the Methodist DeBakey Heart & Vascular Center (MDHVC) echocardiography core laboratory at The Methodist Hospital in Houston. By selecting AG Mednet quality assurance and compliance...
Hansen Medical to Exhibit Magellan Robotic System at 8th Annual European Symposium of Vascular Biomaterials in France
May 6, 2013 8:03 am | by The Associated Press | News | CommentsHansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will be exhibiting its Magellan Robotic System at the 8th Annual European Symposium of Vascular Biomaterials (ESVB) from Friday, May 10th to Monday, May 13th at the Strasbourg Hilton in...
Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
May 3, 2013 1:00 pm | by PR Newswire | News | CommentsHUDSON, N.H., May 3, 2013 /PRNewswire/ -- Atrium Medical Corporation, a business unit of MAQUET Cardiovascular, today announced the 1-year results of the INFUSE-AMI (Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. Dr. Gregg Stone, the...
Researchers Determine Where Best to Place Defibrillators
May 3, 2013 9:55 am | by University of Toronto Faculty of Applied Science & Engineering | News | CommentsPrompt use of an automated external defibrillator, or AED, can greatly increase the survival rates of people who suffer a cardiac arrest. And MIE Professor Tim Chan, working with Dr. Laurie Morrison at St. Michael's Hospital, has developed a formula to determine where best to place these costly but life-saving devices.
St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study
May 3, 2013 9:46 am | by Business Wire | News | CommentsSt. Jude Medical, a global medical device company, today announced first enrollment of its MultiPoint Pacing clinical study to build upon its first- to-market Quadripolar Pacing System. Patients will be implanted with the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Quartet lead to assess pacing in multiple locations in the heart.
Kips Bay Medical Announces the First eSVS Mesh Implant by the Mayo Clinic
May 3, 2013 9:37 am | by Business Wire | News | CommentsManny Villafaña, Chairman and CEO of Kips Bay Medical announced that on April 30, 2013, the Mayo Clinic performed its first implant of an eSVS Mesh at its Rochester, Minnesota facility. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. FDA in a number of preeminent cardiac surgery centers in both Europe and the United States.
Laser-Structured, High-Performance Polymers are Ideal Combination for Miniaturization
May 2, 2013 3:12 pm | by Anthony Verrocchi, Technical Marketing Engineer, Ticona Engineering Polymers | Ticona Engineering Polymers | Blogs | CommentsMiniaturization of medical devices is dependent upon the reliability of their assembled components, which is crucial for proper functioning devices. Miniaturization creates material challenges—especially in electronic medical device applications such as implantable cardiac devices.
Robotic Angioplasty Achieves 97.6 Percent Clinical Success Rate
May 2, 2013 2:39 pm | by Business Wire | News | CommentsCorindus Vascular Robotics, a leading developer of precision vascular robotics, has announced that the Journal of American College of Cardiology published the results from its CorPath PRECISE study in the April 2013 issue. Results of the trial demonstrate the CorPath System is safe and feasible for patients, with significantly lower harmful radiation exposure to the operator.
Closest to Operating on a Live Patient - Simulated Training for Vascular Surgeons and Cardiologists
May 1, 2013 10:00 am | by PR Newswire | News | CommentsCLEVELAND, Ohio, May 1, 2013 /PRNewswire/ -- Simbionix USA Corporation, the world's leading provider of medical education and simulation training, is proud to announce the release of various training modules for the ANGIO Mentor™ endovascular simulator.
PLC Systems Receives First European Patent for RenalGuard(R)
May 1, 2013 8:00 am | by The Associated Press | News | CommentsPLC Systems Inc. (OTCQB: PLCSF), a company focused on innovative medical device technologies, today announced it has been granted its first patent for RenalGuard® by the European Patent Office (EU Patent Number 2010268). This patent covers the core RenalGuard device and its redundant...
MD&M East 2013
April 30, 2013 4:30 pm | by MDT Staff | EventsThe newly reformatted MD&M East four day conference running alongside the tradeshow, covers everything you need to know from concept development to supplier management, giving you the essential updates to successfully management every step in the product development efficiently and cost effectively.
